2. Signaling Pathways
  3. Cell Cycle/DNA Damage
    Epigenetics
  4. Aurora Kinase
  5. Aurora C Isoform

Aurora C

 

Aurora C Related Products (14):

Cat. No. Product Name Effect Purity
  • HY-10161
    Tozasertib
    		Inhibitor 99.93%
    Tozasertib (VX 680; MK-0457) is an inhibitor of Aurora A/B/C kinases with Kis of 0.6, 18, 4.6 nM, respectively.
  • HY-14711
    Reversine
    		Inhibitor 99.22%
    Reversine is a novel class of ATP-competitive Aurora kinase inhibitor with IC50s of 400, 500 and 400 nM for Aurora A, Aurora B and Aurora C, respectively.
  • HY-13253
    AMG 900
    		Inhibitor 99.05%
    AMG 900 is a potent and highly selective pan-Aurora kinases inhibitor with IC50 of 5 nM, 4 nM and 1 nM for Aurora A, B and C, respectively.
  • HY-70044
    GSK-1070916
    		Inhibitor 99.55%
    GSK-1070916 is a potent and selective ATP-competitive inhibitor of aurora B and aurora C with Kis of 0.38 and 1.5 nM, respectively, and is >250- fold selective over Aurora A.
  • HY-10179
    Danusertib
    		Inhibitor 99.44%
    Danusertib is a pyrrolo-pyrazole and aurora kinase inhibitor with IC50 of 13, 79, and 61 nM for Aurora A, B, and C, respectively.
  • HY-123610
    BRD-7880
    		Inhibitor
    BRD-7880 is a potent and highly specific inhibitor of Aurora Kinase B (AURKB) and Aurora Kinase C (AURKC), with IC50 values of 7 nM and 12 nM, respectively.
  • HY-12003
    SNS-314 mesylate
    		Inhibitor 99.53%
    SNS-314 mesylate is a potent and selective aurora kinase inhibitor with IC50s of 9, 31, and 6 nM for aurora A, B and C, respectively.
  • HY-18955
    BI-847325
    		Inhibitor 98.15%
    BI-847325 is an ATP competitive dual inhibitor of MEK and aurora kinases (AK) with IC50 values of 4 and 15 nM for human MEK2 and AK-C, respectively. BI-847325 is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.
  • HY-16018A
    Ilorasertib hydrochloride
    		Inhibitor 98.48%
    Ilorasertib (ABT-348) hydrochloride is a potent, orally active and ATP-competitive aurora inhibitor with IC50s of116, 5, 1 nM for aurora A, aurora B, aurora C, respectively. Ilorasertib hydrochloride also is a potent VEGF, PDGF inhibitor. Ilorasertib hydrochloride has the potential for the research of acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS).
  • HY-10804
    CCT 137690
    		Inhibitor 99.54%
    CCT 137690 is a potent and orally available aurora kinase inhibitor with IC50s of 15, 25, and 19 nM for aurora A, B and C, respectively.
  • HY-12049
    CCT129202
    		Inhibitor ≥98.0%
    CCT129202 is an aurora kinase inhibitor with IC50s of 42, 198, and 227 nM for aurora A, B and C, respectively.
  • HY-10178
    PHA-680632
    		Inhibitor 98.48%
    PHA-680632 is an aurora kinase inhibitor with IC50s of 27, 135 and 120 nM for aurora A, B and C, respectively.
  • HY-16018
    Ilorasertib
    		Inhibitor 99.86%
    Ilorasertib (ABT-348) is a potent, orally active and ATP-competitive aurora inhibitor with IC50s of116, 5, 1 nM for aurora A, aurora B, aurora C, respectively. Ilorasertib also is a potent VEGF, PDGF inhibitor. Ilorasertib has the potential for the research of acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS).
  • HY-108344
    SNS-314
    		Inhibitor
    SNS-314 is a potent and selective aurora kinase inhibitor with IC50s of 9, 31, and 6 nM for aurora A, B and C, respectively.